US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist
  • 71.420
  • +0.270+0.38%
Close Nov 1 16:00 ET
  • 71.440
  • +0.020+0.03%
Post 18:13 ET
221.44BMarket Cap34.67P/E (TTM)

AstraZeneca Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
13.33%12.94B
16.55%12.68B
3.29%45.81B
7.29%12.02B
4.64%11.49B
5.99%11.42B
-4.49%10.88B
18.53%44.35B
-6.69%11.21B
11.31%10.98B
Operating revenue
13.33%12.94B
16.55%12.68B
3.29%45.81B
7.29%12.02B
4.64%11.49B
5.99%11.42B
-4.49%10.88B
18.53%44.35B
-6.69%11.21B
11.31%10.98B
Cost of revenue
11.38%2.18B
16.43%2.22B
-33.27%8.27B
-20.41%2.31B
-29.75%2.1B
-34.62%1.96B
-45.74%1.91B
-0.37%12.39B
-37.30%2.9B
-20.63%2.98B
Gross profit
13.74%10.76B
16.57%10.46B
17.47%37.54B
16.96%9.72B
17.46%9.4B
21.65%9.46B
13.90%8.97B
27.94%31.96B
12.47%8.31B
30.95%8B
Operating expense
14.41%8.01B
10.20%7.35B
5.00%28.82B
20.56%7.71B
10.19%7.44B
-3.23%7B
-4.79%6.67B
9.27%27.45B
-27.90%6.4B
-13.21%6.76B
Selling and administrative expenses
-1.09%5.06B
10.42%4.63B
1.32%18.22B
4.65%3.98B
11.95%4.93B
6.38%5.12B
-15.55%4.19B
15.36%17.98B
-26.11%3.81B
4.58%4.4B
-Selling and marketing expense
0.76%132M
0.75%135M
1.32%18.22B
1.27%17.83B
2.38%129M
1.55%131M
7.20%134M
15.36%17.98B
15.30%17.6B
5.00%126M
-General and administrative expense
-1.14%4.93B
10.74%4.5B
----
----
12.23%4.8B
6.52%4.99B
-16.14%4.06B
----
----
4.57%4.28B
Research and development costs
12.79%3.01B
6.59%2.78B
12.02%10.94B
17.07%3.07B
5.13%2.58B
4.75%2.67B
22.41%2.61B
0.27%9.76B
1.59%2.63B
-31.91%2.46B
Other operating expenses
----
----
-18.00%164M
----
33.96%-70M
----
----
-35.06%200M
----
-186.49%-106M
Operating profit
11.81%2.75B
34.97%3.12B
93.31%8.72B
4.92%2B
56.95%1.95B
355.66%2.46B
162.87%2.31B
3,346.04%4.51B
228.45%1.91B
174.37%1.25B
Net non-operating interest income expense
6.54%-343M
-5.23%-302M
-3.12%-1.29B
-9.58%-343M
10.19%-291M
-25.26%-367M
10.03%-287M
-1.30%-1.25B
-0.64%-313M
-1.25%-324M
Non-operating interest income
56.25%100M
42.31%111M
271.60%301M
109.68%65M
573.33%101M
255.56%64M
358.82%78M
88.37%81M
3,000.00%31M
0.00%15M
Non-operating interest expense
2.78%443M
13.15%413M
19.47%1.59B
18.60%408M
15.63%392M
38.59%431M
8.63%365M
4.23%1.33B
10.26%344M
1.19%339M
Other net income (expense)
Special income (charges)
----
--0
29.93%-529M
5.64%-770M
----
----
--241M
-163.18%-755M
---816M
----
-Less：Restructuring and merger&acquisition
----
----
185.71%520M
----
----
----
----
333.33%182M
----
----
-Less:Other special charges
----
----
-98.43%9M
-60.57%250M
----
----
---241M
146.32%573M
--634M
----
Income before tax
14.80%2.4B
23.78%2.8B
175.85%6.9B
15.30%897M
79.18%1.65B
745.34%2.09B
309.04%2.26B
1,043.77%2.5B
222.33%778M
146.08%922M
Income tax
75.00%469M
35.37%620M
218.43%938M
50.00%-62M
138.06%274M
337.17%268M
177.58%458M
-108.42%-792M
57.24%-124M
-105.71%-720M
Net income
5.93%1.93B
20.84%2.18B
81.02%5.96B
6.32%959M
-16.08%1.38B
405.56%1.82B
364.95%1.8B
2,763.48%3.29B
360.69%902M
199.45%1.64B
Net income continuous Operations
5.93%1.93B
20.84%2.18B
81.02%5.96B
6.32%959M
-16.08%1.38B
405.56%1.82B
364.95%1.8B
2,763.48%3.29B
360.69%902M
199.45%1.64B
Minority interest income
-50.00%1M
0.00%1M
20.00%6M
-200.00%-1M
100.00%4M
2M
-50.00%1M
66.67%5M
0.00%1M
100.00%2M
Net income attributable to the parent company
6.00%1.93B
20.85%2.18B
81.11%5.96B
6.55%960M
-16.22%1.37B
405.00%1.82B
367.10%1.8B
2,835.71%3.29B
359.65%901M
199.27%1.64B
Preferred stock dividends
Other preferred stock dividends
0
0
0
0
0
0
0
0
0
0
Net income attributable to common stockholders
6.00%1.93B
20.85%2.18B
81.11%5.96B
6.55%960M
-16.22%1.37B
405.00%1.82B
367.10%1.8B
2,835.71%3.29B
359.65%901M
199.27%1.64B
Basic earnings per share
5.98%0.62
21.55%0.705
81.13%1.92
6.90%0.31
-16.04%0.445
408.70%0.585
364.00%0.58
2,550.00%1.06
363.64%0.29
196.36%0.53
Diluted earnings per share
5.98%0.62
20.69%0.7
80.57%1.905
6.90%0.31
-16.19%0.44
408.70%0.585
364.00%0.58
2,537.50%1.055
363.64%0.29
195.45%0.525
Dividend per share
0
0.00%0.985
0.00%1.45
0
0.00%0.465
0
0.00%0.985
3.57%1.45
0
3.33%0.465
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
--
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue 13.33%12.94B16.55%12.68B3.29%45.81B7.29%12.02B4.64%11.49B5.99%11.42B-4.49%10.88B18.53%44.35B-6.69%11.21B11.31%10.98B
Operating revenue 13.33%12.94B16.55%12.68B3.29%45.81B7.29%12.02B4.64%11.49B5.99%11.42B-4.49%10.88B18.53%44.35B-6.69%11.21B11.31%10.98B
Cost of revenue 11.38%2.18B16.43%2.22B-33.27%8.27B-20.41%2.31B-29.75%2.1B-34.62%1.96B-45.74%1.91B-0.37%12.39B-37.30%2.9B-20.63%2.98B
Gross profit 13.74%10.76B16.57%10.46B17.47%37.54B16.96%9.72B17.46%9.4B21.65%9.46B13.90%8.97B27.94%31.96B12.47%8.31B30.95%8B
Operating expense 14.41%8.01B10.20%7.35B5.00%28.82B20.56%7.71B10.19%7.44B-3.23%7B-4.79%6.67B9.27%27.45B-27.90%6.4B-13.21%6.76B
Selling and administrative expenses -1.09%5.06B10.42%4.63B1.32%18.22B4.65%3.98B11.95%4.93B6.38%5.12B-15.55%4.19B15.36%17.98B-26.11%3.81B4.58%4.4B
-Selling and marketing expense 0.76%132M0.75%135M1.32%18.22B1.27%17.83B2.38%129M1.55%131M7.20%134M15.36%17.98B15.30%17.6B5.00%126M
-General and administrative expense -1.14%4.93B10.74%4.5B--------12.23%4.8B6.52%4.99B-16.14%4.06B--------4.57%4.28B
Research and development costs 12.79%3.01B6.59%2.78B12.02%10.94B17.07%3.07B5.13%2.58B4.75%2.67B22.41%2.61B0.27%9.76B1.59%2.63B-31.91%2.46B
Other operating expenses ---------18.00%164M----33.96%-70M---------35.06%200M-----186.49%-106M
Operating profit 11.81%2.75B34.97%3.12B93.31%8.72B4.92%2B56.95%1.95B355.66%2.46B162.87%2.31B3,346.04%4.51B228.45%1.91B174.37%1.25B
Net non-operating interest income expense 6.54%-343M-5.23%-302M-3.12%-1.29B-9.58%-343M10.19%-291M-25.26%-367M10.03%-287M-1.30%-1.25B-0.64%-313M-1.25%-324M
Non-operating interest income 56.25%100M42.31%111M271.60%301M109.68%65M573.33%101M255.56%64M358.82%78M88.37%81M3,000.00%31M0.00%15M
Non-operating interest expense 2.78%443M13.15%413M19.47%1.59B18.60%408M15.63%392M38.59%431M8.63%365M4.23%1.33B10.26%344M1.19%339M
Other net income (expense)
Special income (charges) ------029.93%-529M5.64%-770M----------241M-163.18%-755M---816M----
-Less：Restructuring and merger&acquisition --------185.71%520M----------------333.33%182M--------
-Less:Other special charges ---------98.43%9M-60.57%250M-----------241M146.32%573M--634M----
Income before tax 14.80%2.4B23.78%2.8B175.85%6.9B15.30%897M79.18%1.65B745.34%2.09B309.04%2.26B1,043.77%2.5B222.33%778M146.08%922M
Income tax 75.00%469M35.37%620M218.43%938M50.00%-62M138.06%274M337.17%268M177.58%458M-108.42%-792M57.24%-124M-105.71%-720M
Net income 5.93%1.93B20.84%2.18B81.02%5.96B6.32%959M-16.08%1.38B405.56%1.82B364.95%1.8B2,763.48%3.29B360.69%902M199.45%1.64B
Net income continuous Operations 5.93%1.93B20.84%2.18B81.02%5.96B6.32%959M-16.08%1.38B405.56%1.82B364.95%1.8B2,763.48%3.29B360.69%902M199.45%1.64B
Minority interest income -50.00%1M0.00%1M20.00%6M-200.00%-1M100.00%4M2M-50.00%1M66.67%5M0.00%1M100.00%2M
Net income attributable to the parent company 6.00%1.93B20.85%2.18B81.11%5.96B6.55%960M-16.22%1.37B405.00%1.82B367.10%1.8B2,835.71%3.29B359.65%901M199.27%1.64B
Preferred stock dividends
Other preferred stock dividends 0000000000
Net income attributable to common stockholders 6.00%1.93B20.85%2.18B81.11%5.96B6.55%960M-16.22%1.37B405.00%1.82B367.10%1.8B2,835.71%3.29B359.65%901M199.27%1.64B
Basic earnings per share 5.98%0.6221.55%0.70581.13%1.926.90%0.31-16.04%0.445408.70%0.585364.00%0.582,550.00%1.06363.64%0.29196.36%0.53
Diluted earnings per share 5.98%0.6220.69%0.780.57%1.9056.90%0.31-16.19%0.44408.70%0.585364.00%0.582,537.50%1.055363.64%0.29195.45%0.525
Dividend per share 00.00%0.9850.00%1.4500.00%0.46500.00%0.9853.57%1.4503.33%0.465
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP
Audit Opinions ----Unqualified Opinion--------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Infectious Disease
Infectious Disease
Intraday+0.80%